| 产品描述: | EAI001 是一个有效的选择性突变体表皮生长因子受体 (EGFR) 变构抑制剂,抑制 EGFRL858R/T790M 的 IC50 值为 24 nM。EAI001 可用于癌症研究。 |
| 靶点: |
EGFR |
| 体外研究: |
EAI001 (50 μM) binds to EGFR T790M/C797S/V948R that lies deep inside the EGFR towards the ATP binding site and C-helix. EAI001 showed inhibitory activity due to hydrophobic interaction with amino acid Ile759, Leu747, Leu788, Leu777 and Met766[1]. |
| 参考文献: |
[1]. Maity S, et, al. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol Rep. 2020 Aug;72(4):799-813. [Content Brief]
[2]. Tinivella A, et, al. Investigating the selectivity of allosteric inhibitors for mutant t790m egfr over wild type using molecular dynamics and binding free energy calculations. 2018 Dec 4;3(12):16556-62. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.862 ml |
14.31 ml |
28.62 ml |
| 5 mM |
0.572 ml |
2.862 ml |
5.724 ml |
| 10 mM |
0.286 ml |
1.431 ml |
2.862 ml |
| 50 mM |
0.057 ml |
0.286 ml |
0.572 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |